{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:19:20Z","timestamp":1791389960627,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","award":["Grant No. 25-2ZJZ08002-02"],"award-info":[{"award-number":["Grant No. 25-2ZJZ08002-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00977-1","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:00:19Z","timestamp":1781121619000},"page":"1973-1992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China"],"prefix":"10.1007","volume":"15","author":[{"given":"Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinQuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"977_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570\u201381.","journal-title":"N Engl J Med"},{"key":"977_CR2","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s00415-023-11733-y","volume":"270","author":"NE Gilhus","year":"2023","unstructured":"Gilhus NE. Myasthenia gravis, respiratory function, and respiratory tract disease. J Neurol. 2023;270:3329\u201340.","journal-title":"J Neurol"},{"key":"977_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68:8\u201319.","journal-title":"Muscle Nerve"},{"key":"977_CR4","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology. 2020;94:e299\u2013313.","journal-title":"Neurology"},{"key":"977_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","volume":"272","author":"SNM Binks","year":"2025","unstructured":"Binks SNM, Morse IM, Ashraghi M, Vincent A, Waters P, Leite MI. Myasthenia gravis in 2025: five new things and four hopes for the future. J Neurol. 2025;272:226.","journal-title":"J Neurol"},{"key":"977_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T.Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"key":"977_CR7","doi-asserted-by":"crossref","unstructured":"Corrigendum. Adv Neurol Disord. 2018;11:1756286418765591.","DOI":"10.1177\/1756286418765591"},{"key":"977_CR8","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"key":"977_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20:526\u201336.","journal-title":"Lancet Neurol."},{"key":"977_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C,\u00a0Duan RS, Yang H, et al. Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase\u00a0II study. Neurol Ther. 2022;11:815\u201334.","journal-title":"Neurol Ther"},{"key":"977_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V,Dru\u017cd\u017c A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase\u00a03 study. Lancet Neurol. 2023;22:383\u201394.","journal-title":"Lancet Neurol"},{"key":"977_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase\u00a02 vivacity-MG study. Neurology. 2024;102:e207937.","journal-title":"Neurology"},{"key":"977_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M,et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase\u00a03, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976\u201386.","journal-title":"Lancet Neurol"},{"key":"977_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R,et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1:EVIDoa2100066.","journal-title":"NEJM Evid"},{"key":"977_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A,et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase\u00a03 study. Lancet Neurol. 2023;22:395\u2013406.","journal-title":"Lancet Neurol"},{"key":"977_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A,et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79:1105\u201312.","journal-title":"JAMA Neurol"},{"key":"977_CR17","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E, et al. A phase\u00a03 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392:2309\u201320.","journal-title":"N Engl J Med"},{"key":"977_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16322","volume":"31","author":"J Yin","year":"2024","unstructured":"Yin J, Zhao M, Xu X,et al. A multicenter, randomized, open-label, phase\u00a02 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol. 2024;31:e16322.","journal-title":"Eur J Neurol"},{"key":"977_CR19","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","volume":"96","author":"R Mantegazza","year":"2021","unstructured":"Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology. 2021;96:e610\u20138.","journal-title":"Neurology"},{"key":"977_CR20","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. 2024;271:6209\u201319.","journal-title":"J Neurol"},{"key":"977_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96:114\u201322.","journal-title":"Neurology"},{"key":"977_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000539577","volume":"59","author":"F Sciancalepore","year":"2025","unstructured":"Sciancalepore F, Sciancalepore F, Lombardi N, et al. Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: a systematic review. Neuroepidemiology. 2025;59:579\u201392.","journal-title":"Neuroepidemiology"},{"key":"977_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023\u201336.","journal-title":"Lancet Neurol"},{"key":"977_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.","journal-title":"Ther Adv Neurol Disord"},{"key":"977_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs. 2025;39:185\u2013213.","journal-title":"BioDrugs"},{"key":"977_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s13760-022-02162-1","volume":"123","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Ozawa Y, Yasuda M, Onishi Y, Akamine H, Kuwabara S. Minimal symptom expression achievement over time in generalized myasthenia gravis. Acta Neurol Belg. 2023;123:979\u201382.","journal-title":"Acta Neurol Belg"},{"key":"977_CR27","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/ene.14820","volume":"28","author":"R \u00c1lvarez-Velasco","year":"2021","unstructured":"\u00c1lvarez-Velasco R, Guti\u00e9rrez-Guti\u00e9rrez G, Trujillo JC, et al. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. Eur J Neurol. 2021;28:2083\u201391.","journal-title":"Eur J Neurol"},{"key":"977_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103669","volume":"23","author":"C Rita","year":"2024","unstructured":"Rita C, Vinciguerra C, Magro D, Di Stefano V, Monastero R. Towards personalized management of myasthenia gravis phenotypes: from the role of multi-omics to the emerging biomarkers and therapeutic targets. Autoimmun Rev. 2024;23:103669.","journal-title":"Autoimmun Rev"},{"key":"977_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200331","volume":"12","author":"F Stascheit","year":"2025","unstructured":"Stascheit F, Sousa CDF, Aigner A, et al. Ravulizumab and efgartigimod in myasthenia gravis: a real-world study. Neurol Neuroimmunol Neuroinflamm. 2025;12:e200331.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"977_CR30","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11:2212\u201321.","journal-title":"Ann Clin Transl Neurol"},{"key":"977_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241309431","volume":"17","author":"L Jin","year":"2024","unstructured":"Jin L, He D, Zeng Q, et al. Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study. Ther Adv Neurol Disord. 2024;17:17562864241309431.","journal-title":"Ther Adv Neurol Disord"},{"key":"977_CR32","doi-asserted-by":"publisher","first-page":"175628642090420","DOI":"10.1177\/1756286420904207","volume":"13","author":"M Oyama","year":"2020","unstructured":"Oyama M, Okada K, Masuda M, et al. Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord. 2020;13:1756286420904207.","journal-title":"Ther Adv Neurol Disord"},{"key":"977_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123628","volume":"476","author":"JF Howard Jr","year":"2025","unstructured":"Howard JF Jr, Dodig D, Zeinali L, et al. First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab. J Neurol Sci. 2025;476:123628.","journal-title":"J Neurol Sci"},{"key":"977_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","volume":"18","author":"GI Wolfe","year":"2019","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18:259\u201368.","journal-title":"Lancet Neurol"},{"key":"977_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/EB.S389629","volume":"15","author":"R Behbehani","year":"2023","unstructured":"Behbehani R. Ocular myasthenia gravis: a current overview. Eye Brain. 2023;15:1\u201313.","journal-title":"Eye Brain"},{"key":"977_CR36","first-page":"257","volume":"7","author":"WT Cornblath","year":"2018","unstructured":"Cornblath WT. Treatment of ocular myasthenia gravis. Asia Pac J Ophthalmol. 2018;7:257\u20139.","journal-title":"Asia Pac J Ophthalmol"},{"issue":"5","key":"977_CR37","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/mus.70183","volume":"73","author":"S Shi","year":"2026","unstructured":"Shi S, Zhang Y, Yang W, You P, Cheng X, Niu Q.\u00a0Safety and effectiveness of eculizumab in patients with refractory ocular or ocular-predominant myasthenia gravis: a case series. Muscle Nerve. 2026;73(5):887\u201391.","journal-title":"Muscle Nerve"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00977-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:33Z","timestamp":1784819493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00977-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00977-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, and Zhijun Li declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by all the necessary ethics committees and institutional review boards at each trial site. The institutional review board approval number from the leading institution for this study (Tongji Hospital) is TJ-JRB202411058. This retrospective study was granted a waiver of informed consent because it used de-identified data. All procedures rigorously adhered to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}